Abstract The recent finding that Th17 infiltration of ovarian tumors positively predicts patient outcomes suggests that Th17 responses play a protective role in ovarian tumor immunity. This observation has led to the question of whether Th17 cells could be induced or expanded to therapeutic advantage by tumor vaccination. In this study, we show that treatment of ovarian tumor antigen-loaded, cytokine-matured human dendritic cells (DC) with a combination of IL-15 and a p38 MAP kinase inhibitor offers potent synergy in antagonism of CD4
Introduction
Immunotherapy based on dendritic cell (DC) stimulation of ovarian tumor antigen-specific T cell responses has strong potential as an alternative treatment to prevent disease recurrence or progression after first-line therapy for ovarian cancer, but tumor-associated immunosuppression through recruitment and expansion of CD4
? regulatory T cells (Treg) remains a significant barrier to effective treatment. Groundbreaking studies showed that Treg are recruited to ovarian tumors by the chemokine CCL22 (which is highly expressed by ovarian tumors), and that the presence of Treg confers immune privilege and is associated with a poor prognosis and increased mortality [1] . Other investigators have corroborated these observations, showing that high expression of the forkhead box transcription factor foxp3, which is preferentially expressed by CD4
? Treg, is an independent prognostic factor for reduced overall survival in ovarian cancer [2] , and that a high CD8
? T cell/Treg ratio is associated with a more favorable prognosis for this disease [3] .
In sharp contrast with the evidence that Treg infiltration is associated with poor outcomes in ovarian cancer, Th17 T cell infiltration correlates with more favorable clinical outcomes [4] . Tumor-infiltrating Th17 cells were positively associated with effector cells and negatively associated with Treg infiltration [4] , with the latter relationship arguably being founded on the known reciprocal regulation of Treg and Th17 differentiation [5, 6] . These observations have led to the question of whether Th17 cells could be induced or expanded to therapeutic advantage, either by tumor vaccines or adoptive immunotherapy [7, 8] .
Our approach is based on the premise that active immunotherapy, and particularly dendritic cell (DC) vaccination, designed to drive a tumor antigen-specific Th17 T cell response holds the potential to be of clinical benefit for patients with ovarian cancer. DC are remarkable for their plasticity in directing T cell differentiation and effector function, and thus, the key to success may reside in our ability to educate DC to drive ovarian tumor antigenspecific Th17 responses. Several recent studies have indicated that regulation of the p38 and ERK MAPK signal transduction pathways in DC plays a central role in direction of T cell differentiation. Inhibition of MEK 1/2 and ERK MAPK signaling promotes IL-12 production and Th1 T cell responses, whereas inhibition of p38 MAPK increases signal transduction through ERK 1/2 and blocks IL-12 production [9] . At face value, these observations suggest that inhibition of p38 MAPK signaling would be disadvantageous for DC-driven anti-tumor T cell responses, since this would abrogate Th1 responses. However, p38 inhibition promotes differentiation and survival of monocyte-derived DC [10] , and p38 inhibition or MEK/ ERK MAPK activation restores deficiencies in DC function in myeloma patients [11] , suggesting that treatment of DC with pharmacological inhibitors of p38 signaling may confer benefit. Furthermore, p38 MAPK signaling in DC is associated with increased expression of IL-10 and the induction of tolerance in a mouse model of melanoma, thus contributing to the suppression of anti-tumor T cell responses, whereas inhibition of p38 signaling in DC from tumor-bearing mice markedly suppressed expression of IL-10 and restored the capacity of DC to stimulate T cells [12] . Of particular significance, blockade of the p38 pathway can attenuate regulatory T cell induction by DC and enhance the efficacy of DC vaccination [13] , whereas blockade of the ERK pathway suppresses DC-driven Th17 responses [14] , suggesting that p38 blockade (which enhances ERK phosphorylation) may favor a switch from Treg induction to Th17 differentiation and expansion.
In this study, we show that treatment of ovarian tumor antigen-loaded, cytokine-matured DC with a combination of IL-15 and a p38 MAPK inhibitor (p38i) offers potent synergy in antagonism of Treg induction and redirection toward Th17 responses that correlate with strong CD8 ? CTL activation. These observations open the door to the development of innovative DC vaccination strategies to boost Th17 immunity in ovarian cancer patients.
Materials and methods

Human subjects
Ovarian cancer patients (n = 6) were recruited from patients attending the Women's Oncology clinic in the Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, under an IRB-approved protocol. Blood samples were drawn at the time of surgery. Further blood draws (to a maximum of 5 draws of 70 mL each) were taken at any time up to 1 year following enrollment into the study. Healthy adult volunteers (n = 3) also donated blood for this study. Peripheral blood leukocytes (PBL) were recovered by gradient centrifugation over Lymphoprep (Greiner Bio-One), and cryopreserved in liquid nitrogen.
Lymphoblastoid cell lines (LCL)
Epstein-Barr virus-transformed LCL were established from by infection of PBL with the B95.8 strain of EBV, followed by culture in RPMI 1,640 medium supplemented with 3 mM glutamine, 5 9 10 -5 M 2-mercaptoethanol (Sigma) and 10 % fetal bovine serum (Valley Biomedical) (RPMI/10) and 1.0 lg/ml Cyclosporin A (CsA). LCL were fed after 7 days by a half change of RPMI/10 supplemented with CsA. After 14 days, CsA was withdrawn, and LCL were maintained in RPMI/10.
Dendritic cell and T cell culture
For the preparation of DC, PBL were placed in 12-well plates (Costar) at a concentration of up to 5 9 10 6 /well in DC medium (CellGenix GmbH). After incubation for 2-3 h at 37°C, non-adherent cells were removed, the adherent cells were rinsed with phosphate-buffered saline (PBS) and 1.5 ml of DC medium was added to each well, plus 800 U/ml GM-CSF (Sargramostim, Genzyme), 500 U/ml IL-4 (CellGenix), 10 ng/ml IL-15 (CellGenix), and 10 lM p38i (Catalog # 506121, Calbiochem/EMD Chemicals). On days 3 and 5, half the medium was removed and replaced with DC medium plus the same concentration of cytokines and p38 inhibitor. Maturation cytokines (1 lM/ml PGE 2 (Sigma), 1,000 U/ml TNF (CellGenix), and 500 U/ml IL-1 (National Cancer Institute Biological Response Modifiers Program) were added on day 5.
For stimulation of peptide tumor antigen-specific T cell responses, DC were loaded with 50 lg/ml of peptide on day 5 (at the time of addition of maturation cytokines) and the DC were harvested 2 days later. The DC were then washed once with DC medium and used for T cell stimulation at a PBL:DC ratio of 30:1. After 7 days, T cells were collected and restimulated with peptide-loaded irradiated autologous DC at a T cell:DC ratio of between 10:1 and 30:1. T cells were cultured in 10 ml RPMI 1640 medium supplemented with glutamine, 5 9 10 -5 M 2-mercaptoethanol and 10 % human AB serum (Valley Biomedical) (RPMI/10 Hu) in 25 cm 2 tissue culture flasks (Corning). After the second stimulation, CD4
? or CD8 ? T cells were recovered by positive selection with anti-CD4 or anti-CD8 magnetic antibodies (Miltenyi), respectively, yielding populations of at least 95 % purity. During the second and subsequent T cell passages (up to a maximum of 10 restimulations with peptide-loaded DCs), 35 U/ml IL-2 was added to the medium, and the cultures were periodically fed (every 2-3 days) by changing 50-70 % of the medium and addition of fresh IL-2.
Antigen
The hepsin 48-84 peptide was used as a model ovarian tumor antigen for T cell stimulation. Hepsin is a serine protease that is highly overexpressed by ovarian cancer, and is associated with invasion and metastasis [15] . The hepsin 48-84 peptide was selected from combined analysis of DR1, DR4, and DR7 binding motifs, which has a high probability ([85 %) of predicting degenerate HLA DRbinding epitopes, or multiple DR-binding clusters [16] . Prior identification of a multi-epitope peptide (including HLA class I-restricted CD8
? T cell epitopes) from the ovarian tumor antigen stratum corneum chymotryptic enzyme (kallikrein-7) served as a model for this approach [17] . The hepsin 48-84 sequence is QEPLYPVQVSSA-DARLMVFDKTEGTWRLLCSSRSNAR. DCs loaded with hepsin 48-84 peptide efficiently stimulated CD4 ? T cell responses from ovarian cancer patients or healthy adults. Elisa IL-17 was measured by ELISA, using a commercially available kit (R&D systems), according to the manufacturer's instructions. Indoleamine 2,3-dioxygenase (IDO) activity IDO activity was measured as described [18] . Briefly, DC were washed, resuspended in Hanks balanced salts solution (BSS) plus or minus 100 lM tryptophan, and incubated at 37°C for 4 hours. Production of kynurenine, the first stable metabolite of tryptophan downstream of IDO, was measured by spectrophotometry. In the first step, 50 ll of 30 % trichloroacetic acid (TCA) was added to 100 ll DC supernatant, and the samples were vortexed and centrifuged at 8,0009g for 5 minutes. An equal volume of Ehrlich reagent (100 mg P-dimethylbenzaldehyde in 2 ml glacial acetic acid) was added to the supernatant from the TCA precipitation, and the optical density at 492 nm was measured. L-kynurenine production was quantified by reference to a standard curve of defined kynurenine concentrations.
Flow cytometry
The following fluorochrome-conjugated antibodies were used:
phos (all from BD Biosciences), FITC-anti-PD-1 (BioLegend), and APC-anti-CTLA-4 (BD PharMingen). Foxp3 and CTLA-4 were stained following fixation and permeabilization (with buffers from eBioscience, according to the manufacturer's protocol). NF-kB p65 phos , ERK 1/2 phos , and p38 phos were stained following fixation (BD Cytofix, Cat. No. 554655) and permeabilization (BD Phosflow permeabilization buffer III, Cat. No. 558050).
Intracellular cytokine expression was assayed following antigen stimulation of CD4
? T cells. Briefly, LCL were loaded overnight with peptide antigen (50 lg/ml in serumfree DC medium), irradiated (7,500 cGy), and washed once with PBS prior to coculture with responder CD4
? T cells. LCL (2.5 9 10 5 /well) and T cells (5 9 10 5 to 1 9 10 6 / well) were placed in 24-well Costar plates and incubated overnight in the presence of Brefeldin A (eBioscience). Intracellular expression of TNFa and IFNc was detected following fixation and permeabilization (fixation/permeabilization buffer concentrate, Cat. No. 00-5123-43, diluent, Cat. No. 00-5223-56, and permeabilization buffer, Cat. No. 00-8333-56, all from eBioscience).
All samples were analyzed with a FACSCalibur flow cytometer, using CellQuest software (BD Biosciences). Appropriate isotype controls were used throughout.
Multiplex analyses of DC cytokine expression and signaling pathways DC cytokine expression was determined with a Milliplex MAP human cytokine/chemokine multiplex assay (Millipore, Cat. No. MPXHCYTO-60 K) for the following analytes: IFNc, IL-IL-1b, IL-6, IL-10, 12(p70), IL-15, TNFa, and MDC (CCL22). Samples were read with a Luminex 100/200 analysis system (Luminex Corp.). DC signaling pathways were analyzed with an 8-plex multi-pathway signaling kit (Milliplex # 48-680, Millipore) for the determination of ERK 1/2, JNK, p38 MAPK, STAT3, STAT5A/B, p70 S6 kinase, CREB, and IjBa phosphoproteins. Samples were read with a Luminex 100/200 analysis system, with unstimulated and activated HeLa cell lysates as internal controls.
Cytotoxicity assays
Cytotoxicity was tested in a standard chromium release assay. Control or peptide antigen-loaded (50 lg/ml) LCL were incubated in serum-free DC medium overnight at 37°C. Peptide pulsed targets were then labeled with 50 lCi Na 2 [
51 Cr]O 4 for an additional hour and washed twice with PBS and once with DC medium before use. Target cells were plated at 1 9 10 4 /well in 96-well roundbottomed plates with effector T cells at the ratios indicated for each assay. Assays were performed in triplicate wells and incubated for 5 hours at 37°C. Released 51 Cr in the supernatants was measured with a Cobra Auto-Gamma Counter (Packard), and the percentage of target cell lysis was calculated.
Statistics
Where appropriate, data are displayed with error bars representing one standard deviation. Significance was calculated through one-way analysis of variance.
Results
CD4
? helper T cell responses and CD8 ? CTL responses
We tested the ability of IL-15 and/or p38i to enhance DCdriven T cell responses to a model ovarian tumor antigen (serine protease hepsin peptide 48-84). Monocyte-derived DC (cultured with GM-CSF and IL-4, followed by maturation with TNFa, IL-1b, and PGE 2 ) induced poor CD4 ? T cell responses, as measured by IFNc and TNFa expression upon antigen stimulation, and expanded a significant foxp3
? T cell population (Fig. 1a) . This was not remedied by DC treatment with IL-15 or p38i, but the combination of both agents markedly enhanced effector CD4
? T cell responses, and dramatically reduced the frequency of foxp3
? CD4 ? T cells (Fig. 1a) . Furthermore, DC treated with both IL-15 and a p38i activated a robust CD8
? CTL response, whereas cytokine-matured DC and DC treated with IL-15 or p38i failed to activate a detectable CTL response against autologous tumor antigen-loaded targets. Representative results from a healthy individual are presented (Fig. 1b) . IL-15/p38i-treated DC were capable of stimulating tumor antigen-specific CD8
? CTL responses from healthy subjects and ovarian cancer patients, but it should be noted that not all subjects were capable of mounting a CD8
? T cell response to hepsin 48-84. The variability is likely attributable to the impact of HLA class I polymorphism on the ability to present CTL epitopes. Tumor antigen-specific CD4
? T cell lines derived by stimulation with IL-15/p38i-treated DC expressed high levels of IL-17 upon antigen activation, but CD4
? T cell lines stimulated with cytokine-matured DC or DC treated with IL-15 or p38i alone failed to express IL-17 (Fig. 1c) . These observations suggest that IL-15/p38i-treated DC redirect tumor antigen-specific CD4
? T cell responses away from activation and expansion of Treg responses and toward a pro-inflammatory Th17 response, and that the Th17 response correlates with activation of a strong CD8 ? CTL response.
Phenotypic profiles of IL-15/p38i-treated DC and responder CD4
? T cells
Flow cytometric analysis of accessory molecule expression by cytokine-matured DC, and DC treated with IL-15 and/or p38i revealed that p38i treatment (with or without IL-15) led to reduced expression of CD80 and CD86 costimulatory molecules, and CD83, a marker of DC maturation (Fig. 2a) . These results suggest that p38i treatment may abrogate DC maturation and function. However, expression of the B7-H1 (PD-L1) coregulatory molecule was also markedly reduced following p38i treatment of DC, by about 10-fold in terms of mean fluorescence intensity (Fig. 2b) . PD-LI expression was tested with DC from two healthy individuals and four OvCa patients, and p38 inhibition markedly reduced PD-L1 expression in every case. There were no differences observed between healthy individuals and ovarian cancer patients. The mean MFI for PD-L1 expression by cytokine-matured DC was 152, and the mean MFI for PD-L1 expression by IL-15/p38i-treated DC was 38 (P \ 0.001). In contrast, DC expression of ICOS-L (B7-H2) was conserved under all treatment conditions (Fig. 2b) . DC maturation is associated with downregulation of CCR5 and other receptors that are responsive to chemokines produced at inflammatory sites [19] , and increased expression of CCR7, which confers responsiveness to CCL19 and CCL21 chemokines, promoting migration to draining lymph nodes via afferent lymphatics [20] . DC treated with IL-15 and/or p38 MAPK inhibition did not express CCR5 and consistently expressed high levels of CCR7, with p38 inhibition further enhancing CCR7 expression (Suppl. Fig. 1 ), suggesting that the migratory capacity of DC would be preserved under these treatments. Multiplex analysis of cytokine expression by DC from four ovarian cancer patients and one normal donor revealed broadly idiosyncratic patterns, without any discernable trends related to DC treatment (Suppl. Fig. 2a-f) , with the exception of a possible trend toward reduced IL-12p70 expression (Suppl. Fig. 2c ). The chemokine CCL22 was consistently expressed at high levels by DC (Suppl. Fig. 2g ), suggesting they possess the capacity to chemoattract CCR4
? T cells (see below).
CTLA-4 expression has been associated with CD4
? Treg phenotype and function [21, 22] , and PD-1 engagement by PD-L1 can induce T cell anergy and impair anti-tumor immunity [23] . CD4 ? T cells stimulated with cytokinematured DC expressed high levels of CTLA-4, whereas IL-15 or p38i treatment of DC was associated with reduced CD4
? T cell expression of CTLA-4, particularly following combined IL-15/p38i treatment of DC (Fig. 3, left) . CD4
? T cell expression of PD-1 was also reduced following stimulation by p38i-treated DC, and to a lesser extent, by IL-15-treated DC (Fig. 3, right) .
Ovarian tumor cells and tumor-associated macrophages express CCL22, which promotes infiltration of CCR4
?
Treg [1] , and may potentially drive migration of CD4
? CCR4 ? Th17 T cells. In addition, ovarian tumors express CXCL12 (stromal-derived factor 1) [24] , which ? T cells stimulated with p38i-treated DC showed enhanced expression of CCR4, relative to CD4
? T cells stimulated with cytokine-matured DC, but showed variably lower expression of CXCR4 (Suppl. Fig. 3 ).
Modulation of DC signal transduction pathways following p38i treatment
To determine the relationship between signaling pathways and DC phenotype and function, phosphorylation of key molecules was investigated by flow cytometry and multiplex analyses. Pharmacologic inhibition of p38 resulted in increased DC accumulation of p38 phos and ERK 1/2 phos (Fig. 4) . Upregulated ERK pathway activity was expected, given that the p38 pathway negatively regulates ERK signaling. Increased levels of p38 phos were observed because the pharmacologic inhibitor of p38 used in these experiments blocks downstream phosphorylation of p38 substrates, rather than phosphorylation of p38 itself. Variable changes in p38 and ERK 1/2 phosphorylation were observed in multiplex assays, but the trends supported the flow cytometric analyses (Suppl. Fig. 4a and 4b) . The JNK pathway did not show any significant changes in activity following inhibition of p38 signaling (Suppl. Fig. 4c ). NF-jB activity, at least as indicated by Rel65 phosphorylation, was diminished following IL-15 treatment, but essentially unchanged following p38 MAPK inhibition (Fig. 4) . However, p38 inhibition decreased levels of activation-induced Ser 32 -phosphorylated IjBa (Suppl. Fig. 4d ), which may be indicative of ubiquitination and proteasomal degradation, resulting in release and nuclear translocation of NF-jB [26, 27] . Phosphorylation of STAT3, STAT5A/B, p70 S6 kinase, and CREB was not altered by treatment of DC with IL-15 and/or p38 inhibition (not shown).
Indoleamine 2,3-dioxygenase (IDO) activity following p38 inhibition IDO expression by DC drives Treg responses [28] and controls the balance between Treg and Th17 differentiation [29, 30] . IL-15 treatment of DC had a minimal impact on IDO activity, but inhibition of p38 signaling in DC almost totally abolished IDO activity, as measured by production of kynurenine (an immediate downstream catabolite of tryptophan degradation by IDO) (Fig. 5) . Statistically significant differences were observed in IDO activity between the p38i-treated DC and DC in which the p38 MAPK pathway was not inhibited (P \ 0.001). There was also a significant difference in IDO activity between cytokinematured DC and IL-15-treated DC (P = 0.001), but there was no difference between the p38i-treated and IL-15/p38i-treated DC. These observations were highly reproducible between normal individuals and ovarian cancer patients, and suggest that abrogation of IDO activity following p38 signaling may contribute to DC stimulation of Th17 responses.
Discussion
It has become increasingly evident in recent years that the immune system is intimately involved with the pathogenesis of ovarian cancer. Numerous mechanisms of immune suppression have been identified, including Treg infiltration [1] , expression of B7-H1 and B7-H4 coinhibitory molecules by tumor cells and tumor-associated antigen-presenting cells and expression of IDO, all of which are associated with poor clinical outcomes for ovarian cancer patients [31] [32] [33] [34] . As a counterweight to these observations, clinical studies have pointed to a role for the immune system in limiting disease progression, suggesting that disease outcomes may be strongly influenced by the balance between immune suppression in the tumor microenvironment versus anti-tumor effector mechanisms. CD3 ? T cell infiltration in ovarian cancer has been associated with prolonged survival, and patients with tumor-infiltrating T cells were more likely to enjoy optimal cytoreductive surgery (itself a positive correlate with disease-free and overall survival), suggesting that T cell immunity may directly limit disease spread [35] . A high CD8 ? T cell/Treg ratio has also been associated with a more favorable prognosis [31] , and most notably, Th17 cell infiltration correlates with markedly improved overall survival in ovarian cancer [4] . Although the current evidence in ovarian cancer presents a strong case for Th17-based immunotherapy or tumor vaccination, studies in other malignancies, notably gastric and colon carcinoma [36, 37] , have indicated a role for the inflammatory and pro-angiogenic properties of IL-17 in tumor development and progression [38] [39] [40] , suggesting that the pro-or anti-tumor impact of Th17 immunity may be predicated by the local environment in which the response is shaped. Differing modes of analysis may also present apparently conflicting results from clinical studies. For example, Derhovanessian and colleagues reported an inverse relationship between CCR4 -
IL-17
? CD4 ? T cell frequencies in peripheral blood and time to progression in prostate cancer, although no such association was observed for CCR4 ?
? CD4 ? T cells in the circulation [41] . Further, a second study indicated that a higher frequency of Th17 prostate-infiltrating lymphocytes was associated with slower disease progression [42] , suggesting that Th17 immunity in the tumor microenvironment may limit prostate tumor spread.
Notwithstanding these concerns, there has been a steady accumulation of experimental evidence that Th17 cells are capable of mediating powerful anti-tumor immunity. Local induction of Th17 responses has also conferred a survival advantage in a mouse model of pancreatic cancer [43] , and tumor growth and pulmonary metastasis was enhanced following injection of the MC38 colon cancer cell line in IL-17-deficient mice [44] , again suggesting a protective role for IL-17-expressing T cells. Furthermore, adoptive transfer of Th17 cells to melanoma-bearing mice had greater therapeutic efficacy than transfer of Th1 cells, and Th17 cells activated tumor-specific CD8 ? T cells that were required for anti-tumor activity [45, 46] . The idea that Th17 cells can promote effective anti-tumor immunity is underlined by a recent report that human Th17 T cells are long-lived effector memory cells with the capacity to mediate effective anti-tumor immunity in collaboration with CD8 T cells [47] . It was further shown that Th17 cells were relatively resistant to apoptosis, and that apoptosis and persistence were regulated by high expression of HIF-1a, suggesting that Th17 cells may have a survival advantage in the hypoxic tumor microenvironment.
In this report, we show that treatment of human monocyte-derived cytokine-matured DC with the combination of IL-15 and inhibition of p38 MAPK signaling confers the ability to stimulate Th17 CD4
? T cell responses associated with strong CD8
? CTL responses. Various phenotypic and functional changes were observed (Fig. 6 ), any or all of which may contribute to Th17 induction. ERK1/2 signaling, which is elevated in p38i-treated DC, has been implicated in DC-driven Th17 responses [14] . The loss of IDO activity may also be critical for Th17 induction, since IDO reportedly plays a pivotal role in the Treg/Th17 balance [28] [29] [30] . Reduced DC expression of B7-H1 following p38 inhibition may also limit expansion of Foxp3
? CD4
?
T cells, as B7-H1 has been associated with differentiation of adaptive Foxp3 ? Treg [48] . In contrast, ICOSL expression on DC was conserved, which may be important, as ICOSL-ICOS signaling has recently been shown to be critical for Th17 responses in humans [49] . In this context, it is also worth noting that p38 inhibition leads to reduced DC expression of CD80 and CD86, potentially leading to reduced costimulation through CD28. At first glance, this may appear to be a drawback for stimulation of effector T cell responses, but CD28 signaling can exert a veto effect on Th17 activation [49, 50] , and thus reduced expression of CD80 and CD86 may indirectly favor a Th17 response. Elucidation of the relative contributions of these key pathways in DC stimulation of Th17 responses will require further investigation.
In conclusion, we have shown that treatment of ovarian tumor antigen-loaded, cytokine-matured DC with a combination of IL-15 and a p38 MAPK inhibitor offers potent synergy in antagonism of Treg induction and redirection toward Th17 responses that correlate with strong CD8
? CTL activation. These observations may contribute to the clinical development of innovative DC vaccination strategies for stimulation of Th17 immunity in ovarian cancer patients. 
